Cost-effectiveness analysis of cisplatin-based chemoradiation to treat patients with unresectable, nonmetastatic head and neck cancer in Brazil

Head & Neck ◽  
2010 ◽  
Vol 33 (8) ◽  
pp. 1199-1205 ◽  
Author(s):  
Alexandra Brentani ◽  
Gilberto de Castro ◽  
Miriam H. Federico
Keyword(s):  
Head And Neck Cancer ◽  
Cost Effectiveness ◽  
Head And Neck ◽  
Neck Cancer ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis

Photobiomodulation in oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis followed by a cost-effectiveness analysis

2020 ◽  
Vol 28 (12) ◽  
pp. 5649-5659
Author(s):  
Thalita Molinos Campos ◽  
Carolina Antunes do Prado Tavares Silva ◽  
Ana Paula Taboada Sobral ◽  
Sergio Sousa Sobral ◽  
Maria Fernanda Setúbal Destro Rodrigues ◽  
...  
Keyword(s):  
Systematic Review ◽  
Head And Neck Cancer ◽  
Cost Effectiveness ◽  
Head And Neck ◽  
Neck Cancer ◽  
Oral Mucositis ◽  
Meta Analysis ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis

scholarly journals Cost-effectiveness analysis of PET-CT-guided management for locally advanced head and neck cancer

2017 ◽  
Vol 85 ◽  
pp. 6-14 ◽  
Author(s):  
A.F. Smith ◽  
P.S. Hall ◽  
C.T. Hulme ◽  
J.A. Dunn ◽  
C.C. McConkey ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Cost Effectiveness ◽  
Head And Neck ◽  
Neck Cancer ◽  
Locally Advanced ◽  
Cost Effectiveness Analysis ◽  
Advanced Head ◽  
Ct Guided ◽  
Effectiveness Analysis ◽  
Pet Ct

scholarly journals A cost-effectiveness analysis of a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy

BMC Cancer ◽  
2011 ◽  
Vol 11 (1) ◽  
Author(s):  
Valesca P Retèl ◽  
Lisette van der Molen ◽  
Frans JM Hilgers ◽  
Coen RN Rasch ◽  
Annemiek AAMHJ L'Ortye ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Cost Effectiveness ◽  
Head And Neck ◽  
Neck Cancer ◽  
Exercise Program ◽  
Cost Effectiveness Analysis ◽  
Advanced Head ◽  
Effectiveness Analysis

scholarly journals Cost-effectiveness analysis of salvage therapies in locoregional previously irradiated head and neck cancer

Head & Neck ◽  
2018 ◽  
Author(s):  
HaYeon Kim ◽  
John A. Vargo ◽  
Sushil Beriwal ◽  
David A. Clump ◽  
James P. Ohr ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Cost Effectiveness ◽  
Head And Neck ◽  
Neck Cancer ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis

scholarly journals Cost-effectiveness analysis of oral nutritional supplements with nutritional counselling in head and neck cancer patients undergoing radiotherapy

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Beatrice Martin ◽  
Emanuele Cereda ◽  
Riccardo Caccialanza ◽  
Paolo Pedrazzoli ◽  
Rosanna Tarricone ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Cost Effectiveness ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Nutritional Counseling ◽  
Effectiveness Analysis ◽  
Life Years ◽  
The Cost

Abstract Objective There is limited evidence regarding the economic effects of nutrition support in cancer patients. This study aims at investigating the cost-effectiveness profile of systematic oral nutritional supplementation (ONS) in head and neck cancer (HNC) patients undergoing radiotherapy (RT) and receiving nutritional counseling. Methods A cost-effectiveness analysis based on a RCT was performed to estimate direct medical costs, life years gained (LYG) and Quality-Adjusted Life Years (QALY) for nutritional counseling with or without ONS at 5-month and 6-year follow up time. Value of information analysis was performed to value the expected gain from reducing uncertainty through further data collection. Results ONS with nutritional counseling produced higher QALY than nutritional counseling alone (0.291 ± 0.087 vs 0.288 ± 0.087), however the difference was not significant (0.0027, P = 0.84). Mean costs were €987.60 vs €996.09, respectively in the treatment and control group (-€8.96, P = 0.98). The Incremental Cost Effectiveness Ratio (ICER) was -€3,277/QALY, with 55.4% probabilities of being cost-effective at a cost-effectiveness threshold of €30,000/QALY. The Expected Incremental Benefit was €95.16 and the Population Expected Value of Perfect Information was €8.6 million, implying that additional research is likely to be worthwhile. At a median 6-year follow up, the treatment group had a significantly better survival rate when adjusting for late effect (P = 0.039). Conclusion Our findings provide the first evidence to inform decisions about funding and reimbursement of ONS in combination with nutritional counseling in HNC patients undergoing RT. ONS may improve quality of cancer care at no additional costs, however further research on the cost-effectiveness of nutritional supplementation is recommended. Trial Registration: ClinicalTrials.gov: NCT02055833. Registered 5th February 2014 https://clinicaltrials.gov/ct2/show/NCT02055833

Sign in / Sign up

Export Citation Format

Share Document